Research never stops

Diabetes

Diabetes Mellitus is an incapacitating chronic disease associated with severe life-long conditions such as cardiovascular diseases, kidney diseases, nerve damage and eye diseases, which require intensive monitoring and control. Diabetes is caused by relative or complete decrease in insulin production and secretion by pancreatic beta cells. Furthermore, diabetes can be caused by the reduced effectiveness of secreted insulin in consequence of the gradual loss of insulin sensitivity of target cells which is called insulin resistance. At present, there is no cure for diabetes and only symptomatic treatment options are available. The most common diabetes types are type 1 and type 2 diabetes.

Currently, about 90-95% of diabetes patients worldwide have type 2 diabetes. According to the International Diabetes Federation, 382 m people worldwide have diabetes (2012: 371 m). Thereof, about 175 m are not yet diagnosed and are at risk of costly and debilitating diabetes complications. It is estimated that about 4.8 million people will have died from diabetes at the end of 2012 (2011: 4.0 million). Concerning the diabetes market volume, $ 548 bn were spent on the treatment of diabetes in 2013 (2012: $ 471 bn).

Evotec generates a first-in-class diabetes pipeline, expanding into disease complications & new mechanisms:

Molecule(s)

Indication
(mechanism)

Partner Status Next milestone Commercials
EVT770 Type 1 and 2 diabetes (beta cell regeneration)

MedImmune/

AstraZeneca

Pre-clinical Phase I € 5 m upfront, high margin research payments, up to € 254 m milestones/product, significant royalties
TargetBCD Type 1 and 2 diabetes (beta cell regeneration) Sanofi

Discovery/

Pre-clinical

ND

€ 3 m upfront,
research payments, potentially over € 300 m milestones, significant royalties

ALM Type 1 and 2 diabetes (beta cell regeneration)

MedImmune/

AstraZeneca
Discovery Phase I € 2 m upfront, high margin research payments, up to € 183 m milestones/product, significant royalties
Various Kidney disease AstraZeneca ND ND Undisclosed upfront, high margin research payments, milestones/product, royalties
TargetEEM Type 1 and 2 diabetes (enteroendocrine mechanisms) Harvard University
Discovery Pharma partnership
TBD
CureNephron Chronic kidney disease Harvard University Discovery Pharma partnership TBD
CureBeta Type 1 and 2 diabetes (beta cell regeneration) Harvard University Discovery
Pharma partnership TBD

Diabetes

MedImmune/EVT770

- read more

Sanofi/TargetBCD

- read more

MedImmune/ALM

- read more

AstraZeneca/Various

- read more

Harvard/TargetEEM

- read more

Harvard/CureNephron

- read more

Harvard/CureBeta

- read more